Microenvironmental Factors and The Role Of Tumor Necrosis Factor Receptor Type 1 (TNFR-1) In Chronic Lymphocytic Leukemia

Blood ◽  
2013 ◽  
Vol 122 (21) ◽  
pp. 4149-4149
Author(s):  
Claudia Duerr ◽  
Angela Schulz ◽  
Sibylle Ohl ◽  
Thorsten Zenz ◽  
Stephan Stilgenbauer ◽  
...  
Keyword(s):  
B Cells ◽  
Chronic Lymphocytic Leukemia ◽  
Tumor Necrosis Factor ◽  
Tumor Necrosis ◽  
Tumor Necrosis Factor Receptor ◽  
Lymphocytic Leukemia ◽  
Receptor Type ◽  
Tnf Α ◽  
Necrosis Factor

Abstract B-cell Chronic Lymphocytic Leukemia (CLL) represents the most common leukemia among adults in the western world and remains still incurable. CLL is characterized by the accumulation of malignant B-cells in the peripheral blood and the lymphoid organs due to apoptosis resistance. Removing the cells from their physiological microenvironment spontaneously drives them into apoptosis in vitro unless they are supported by bystander cells (e.g. stromal cells or accessory leukocytes) or soluble factors such as cytokines produced by these cells. In order to identify differences in the biology of healthy B-cells and the leukemic clones we performed comparative microarray analyses of both cell types before and after cultivation in high cell density that allows cell-cell interactions of CLL cells with accessory leukocytes. These studies revealed the establishment of an inflammatory microenvironment in CLL characterized by the transcriptional upregulation of several cytokines. Antibody array analyses of culture supernatants and blood serum samples confirmed the upregulation of these proteins and their relevance for CLL. The 11 most deregulated cytokines were quantified in the serum of 250 CLL patients of the German CLL8 study cohort and 50 age- and sex-matched controls in order to identify novel predictive or prognostic markers. Bioinformatical analyses of the data are currently ongoing. Among other proteins, we found Tumor Necrosis Factor Receptor Type 1 (TNFR-1) to be significantly upregulated in the malignant B-cells under survival-maintaining cultivation as well as in CLL serum, but not in healthy controls (Figure 1). To exploit the difference in TNFR-1 biology, we treated CLL cells with TNF-α in combination with wogonin which is known to block the survival supporting pathway propagated by TNFR-1 upon TNF-α binding. This combinational treatment strategy effectively triggered Disclosures: No relevant conflicts of interest to declare.

The Role of Tumor Necrosis Factor Receptor Type 1 in Orthodontic Tooth Movement

2007 ◽  
Vol 86 (11) ◽  
pp. 1089-1094 ◽  
Author(s):  
I. Andrade ◽  
T.A. Silva ◽  
G.A.B. Silva ◽  
A.L. Teixeira ◽  
M.M. Teixeira
Keyword(s):  
Tumor Necrosis Factor ◽  
Tumor Necrosis ◽  
Tooth Movement ◽  
Tumor Necrosis Factor Receptor ◽  
Orthodontic Tooth Movement ◽  
Receptor Type ◽  
Periodontal Tissues ◽  
Tnf Α ◽  
Necrosis Factor

Orthodontic tooth movement is dependent on osteoclast activity. Tumor necrosis factor (TNF)-α plays an important role, directly or via chemokine release, in osteoclast recruitment and activation. This study aimed to investigate whether the TNF receptor type 1 (p55) influences these events and, consequently, orthodontic tooth movement. An orthodontic appliance was placed in wild-type mice (WT) and p55-deficient mice (p55−/−). Levels of TNF-α and 2 chemokines (MCP-1/CCL2, RANTES/CCL5) were evaluated in periodontal tissues. A significant increase in CCL2 and TNF-α was observed in both groups after 12 hrs of mechanical loading. However, CCL5 levels remained unchanged in p55−/− mice at this time-point. The number of TRAP-positive osteoclasts in p55−/− mice was significantly lower than that in WT mice. Also, there was a significantly smaller rate of tooth movement in p55−/− mice. Analysis of our data suggests that the TNFR-1 plays a significant role in orthodontic tooth movement that might be associated with changes in CCL5 levels.

Tumor necrosis factor receptor-associated factor 1 gene overexpression in B-cell chronic lymphocytic leukemia: analysis of NF-κB/Rel–regulated inhibitors of apoptosis

Blood ◽  
2002 ◽  
Vol 100 (10) ◽  
pp. 3749-3756 ◽  
Author(s):  
Gerd Munzert ◽  
Dieter Kirchner ◽  
Heike Stobbe ◽  
Lothar Bergmann ◽  
Roland M. Schmid ◽  
...  
Keyword(s):  
B Cells ◽  
Chronic Lymphocytic Leukemia ◽  
Tumor Necrosis Factor ◽  
B Cell ◽  
Tumor Necrosis ◽  
Tumor Necrosis Factor Receptor ◽  
Lymphocytic Leukemia ◽  
Inhibitors Of Apoptosis ◽  
Necrosis Factor ◽  
Cell Chronic Lymphocytic Leukemia

B-cell chronic lymphocytic leukemia (B-CLL) is characterized by a resistance toward apoptosis-inducing agents. Nuclear factor-κB (NF-κB)/Rel has been shown to regulate the expression of antiapoptotic genes, such as members of the inhibitor of apoptosis protein (IAP) and tumor necrosis factor receptor-associated factor (TRAF) gene families. Expression and regulation of NF-κB/Rel–dependent inhibitors of apoptosis have not been collectively studied in B-CLL. We examined expression of known NF-κB/Rel–regulated antiapoptotic genes by RNAse protection assay, real-time polymerase chain reaction, and immunoblotting in patients with B-CLL. TRAF1 and to a lesser extent TRAF2 were overexpressed in B-CLL lymphocytes as compared with normal CD19+ B cells. TRAF1 overexpression did not correlate with markers of disease progression or overall survival. Furthermore, we found high constitutive expression of the IAP genes c-IAP-1, c-IAP-2, and XIAP both in normal and B-CLL lymphocytes. Focusing on the regulation of TRAF1, NF-κB/Rel activity in B-CLL nuclear extracts was shown to bind to TRAF1 promoter elements. However, IκB kinase (IKK) activity was not increased in CLL lymphocytes as compared with normal CD19+ B cells. The known IKK inhibitor sulfasalazine did not compromise TRAF1 expression. Thus, although our study revealed a common expression pattern of NF-κB/Rel–regulated inhibitors of apoptosis, our findings indicate an IKK-independent regulation of TRAF1 in B-CLL.

scholarly journals Tumor Necrosis Factor Induces Tumor Necrosis via Tumor Necrosis Factor Receptor Type 1-Expressing Endothelial Cells of the Tumor Vasculature

2000 ◽  
Vol 156 (4) ◽  
pp. 1171-1176 ◽  
Author(s):  
Benjamin Stoelcker ◽  
Brigitte Ruhland ◽  
Thomas Hehlgans ◽  
Horst Bluethmann ◽  
Thomas Luther ◽  
...  
Keyword(s):  
Endothelial Cells ◽  
Tumor Necrosis Factor ◽  
Tumor Necrosis ◽  
Tumor Necrosis Factor Receptor ◽  
Tumor Vasculature ◽  
Receptor Type ◽  
Necrosis Factor

scholarly journals Distinctive roles of tumor necrosis factor receptor type 1 and type 2 in a mouse disc degeneration model

2021 ◽  
Vol 31 ◽  
pp. 62-72
Author(s):  
Shanzheng Wang ◽  
Guodong Sun ◽  
Pan Fan ◽  
Lei Huang ◽  
Yaofei Chen ◽  
...  
Keyword(s):  
Tumor Necrosis Factor ◽  
Disc Degeneration ◽  
Tumor Necrosis ◽  
Tumor Necrosis Factor Receptor ◽  
Receptor Type ◽  
Necrosis Factor

scholarly journals Tumor necrosis factor induces proliferation of neoplastic B cells from chronic lymphocytic leukemia

Blood ◽  
1989 ◽  
Vol 73 (5) ◽  
pp. 1242-1246 ◽  
Author(s):  
W Digel ◽  
M Stefanic ◽  
W Schoniger ◽  
C Buck ◽  
A Raghavachar ◽  
...  
Keyword(s):  
B Cells ◽  
Chronic Lymphocytic Leukemia ◽  
Tumor Necrosis Factor ◽  
Tumor Necrosis ◽  
Lymphocytic Leukemia ◽  
Membrane Receptors ◽  
Necrosis Factor Alpha ◽  
Proliferative Effect ◽  
Necrosis Factor

Abstract The biologic effects of recombinant tumor necrosis factor-alpha (rTNF- alpha) and the expression of specific TNF membrane receptors on isolated neoplastic B cells from previously untreated patients with chronic lymphocytic leukemia (CLL) were investigated in vitro. Isolated B cells were incubated up to six days with various concentrations of rTNF-alpha (0.1 to 100 ng/mL). B cells from most patients proliferated ranged from two to 104 times that of unstimulated cells from the same patients. An optimal proliferative effect was achieved at 25 ng/mL rTNF- alpha and an incubation time between 96 and 120 hours, whereas a low concentration of rTNF-alpha (1 ng/mL) reduced [3H]TdR incorporation in four cases. Metaphase cells were detected in the rTNF-alpha-stimulated cultures that proliferated in response to rTNF-alpha. B cells from three of ten patients proliferated spontaneously and proliferation was further enhanced in two patients by rTNF-alpha. TNF binding assays gave a value of approximately 390 to 1,400 binding sites/cell for TNF and a dissociation constant (kd) of approximately 60 pmol/L. These data indicate that rTNF-alpha, in contrast to its cytotoxic/cytostatic effects, can also induce proliferation of tumor cells.

Sign in / Sign up

Export Citation Format

Share Document